LONDON: Novo Nordisk signed a analysis tie-up with US biotech agency Metaphore on Thursday to develop next-generation weight problems medicine.
Why it is Vital
Danish drugmaker Novo is attempting to develop past its blockbuster weight problems drug Wegovy with no less than eight different therapies in its R&D pipeline for the situation.
The collaboration will use Metaphore’s tech platform to develop two therapies for weight problems, the businesses stated.
Context
The worldwide marketplace for weight reduction medicine is predicted to achieve no less than $100 billion by the top of the last decade.
Novo in January introduced analysis collaborations with two biotech companies Omega Therapeutics and Cellarity, each of which had been based by US funding agency Flagship Pioneering.
Metaphore was additionally based by Flagship.
By the Numbers
Novo might pay as much as $600 million in numerous milestone funds, in addition to royalties on annual web gross sales of licensed merchandise, Metaphore stated.
Novo’s funds shall be shared between Metaphore and Flagship’s analysis and partnership arm Pioneering Medicines.
Why it is Vital
Danish drugmaker Novo is attempting to develop past its blockbuster weight problems drug Wegovy with no less than eight different therapies in its R&D pipeline for the situation.
The collaboration will use Metaphore’s tech platform to develop two therapies for weight problems, the businesses stated.
Context
The worldwide marketplace for weight reduction medicine is predicted to achieve no less than $100 billion by the top of the last decade.
Novo in January introduced analysis collaborations with two biotech companies Omega Therapeutics and Cellarity, each of which had been based by US funding agency Flagship Pioneering.
Metaphore was additionally based by Flagship.
By the Numbers
Novo might pay as much as $600 million in numerous milestone funds, in addition to royalties on annual web gross sales of licensed merchandise, Metaphore stated.
Novo’s funds shall be shared between Metaphore and Flagship’s analysis and partnership arm Pioneering Medicines.
